Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy

NCT04670913 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Advanced Non Squamous NSCLC

Interventions

DRUG: Camrelizumab
DRUG: Apatinib

Sponsor

Junling Li